San Francisco, CA, United States of America

Alejandra Elena Arbetman

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 2.9

ph-index = 4

Forward Citations = 198(Granted Patents)


Location History:

  • San Francisco, CA (US) (2007 - 2016)
  • Bridgewater, NJ (US) (2021)

Company Filing History:


Years Active: 2007-2021

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Alejandra Elena Arbetman: Innovator in AAV Virion Technology

Introduction

Alejandra Elena Arbetman is a prominent inventor based in San Francisco, CA. She has made significant contributions to the field of gene therapy, particularly through her work on adeno-associated virus (AAV) technology. With a total of 5 patents to her name, Arbetman has established herself as a key figure in the development of innovative therapeutic solutions.

Latest Patents

One of her latest patents focuses on AAV virions with decreased immunoreactivity. This patent describes methods for making and using recombinant AAV virions that include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes. These innovations display decreased immunoreactivity relative to AAV-2, which is crucial for enhancing the efficacy of gene therapies.

Career Highlights

Throughout her career, Arbetman has worked with notable companies such as Genzyme Corporation and Avigen, Inc. Her experience in these organizations has allowed her to refine her expertise in AAV technology and contribute to groundbreaking advancements in the field.

Collaborations

Arbetman has collaborated with esteemed colleagues, including Michael A. Lochrie and Peter C. Colosi. These partnerships have further enriched her research and development efforts, leading to significant innovations in gene therapy.

Conclusion

Alejandra Elena Arbetman is a trailblazer in the field of AAV technology, with a strong portfolio of patents and a career marked by impactful collaborations. Her work continues to influence the landscape of gene therapy and holds promise for future advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…